Similar observations have been made in other tumors, where DPP-4 expression specificity has been validated as a robust biomarker for chronic myeloid leukemia (CML) in peripheral blood. The gene discussed is DPP4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.